MINNETONKA, Minn., March 24, 2026 (GLOBE NEWSWIRE) — Table Trac, Inc. (OTCQX: TBTC), a developer and provider of casino information and management systems that automate and monitor the operations of casinos announced financial results for the year ended December 31, 2025. The 10-K can be found @ http://www.sec.gov 2025 Highlights Record Gross Profit. Record maintenance revenue of $6.15 Million, an approximate 14.4% increase over the prior year. Maintenance revenue accounted for 55.7% of total revenues. Other revenue increased 13.2% as a result of an increase in recurring monthly fees relating to DataTrac and SlotSuite. Table Trac declared and paid quarterly dividends of $0.02 per share in each of the four quarters during 2025. The CasinoTrac system was installed in eight locations during 2025. At the end of 2025, Table Trac had...

Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory biomarkers of cardiovascular risk; Phase 2a proof-of-concept trial planned to initiate in 1H 2026 Indication expansion for BGE-102 into ophthalmology; Phase 1b/2a proof-of-concept trial in diabetic macular edema planned to initiate mid-2026 Completed upsized follow-on public offering of $132.3 million with full exercise of the underwriters’ overallotment option in February 2026 EMERYVILLE, Calif., March 24, 2026 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human...

Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid prescriptions filled from launch through Q1 2026, written by more than 10,000 prescribing eye care professionals Compelling real-world performance of VIZZ, combined with broad prescriber uptake and encouraging early refill trends, reinforces confidence in its best-in-class profile and establishment of a durable new category Management to host conference call today, March 24, 2026, at 8:30am EDT SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first...

ATHENS, Greece and NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) — Heidmar Maritime Holdings Corp. (the “Company” or “Heidmar”) (NASDAQ: HMR) today reported its results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 HighlightsTotal revenues of $25.1 million, up from $5.3 million in Q4 2024. Net loss from continuing operations attributable to shareholders of $4.0 million or $0.07 loss per share. Cash and cash equivalents of $18.6 million as of December 31, 2025.FOURTH QUARTER 2025 RESULTS COMPARED TO FOURTH QUARTER 2024 Total revenues, earned from commissions, management fees and voyage and time charter hire, were $25.1 million for the three months ended December 31, 2025, compared to $5.3 million for the three months ended December 31, 2024. The increase of $19.8 million is mainly...

Electrification is driving new opportunities for Sonepar worldwide, with strong growth across key sectors such as industrial automation, energy storage, grid and infrastructures modernization and rapidly expanding data centers.Sonepar global key figures 2025Sonepar global key figures 2025Sonepar US key figures 2025Sonepar US key figures 2025Paris, France, March 24, 2026 (GLOBE NEWSWIRE) — Sonepar delivered record sales of $37.9 billion in 2025 and strengthened its profitability despite a challenging global economic environment. Electrification is driving new opportunities for Sonepar worldwide, with strong growth across key sectors such as industrial automation, energy storage, grid and infrastructures modernization and rapidly expanding data centers. Sonepar registered over $1.7 billion in sales for the data...

~ Delivered Record Annual Revenue with Full-Year Net PEDMARK® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75% Growth Over Q4 2024 Net Product Sales ~ ~ Executed on 2025 Clinical Data Strategy to Expand Real-World Validation of PEDMARK® Across New Tumor Types and Patient Populations Through Independent, Institution-Led Research ~ ~ Achieved Record Performance with All-Time High Patient Enrollments and Conversion Rates in Q4 2025, Reflecting Strong Field Execution ~ ~ Completed Oversubscribed $42 Million Equity Offerings with Participation from New and Existing Investors ~ ~ Announced Positive Topline Results from Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss ~ ~ Management to Host Conference Call...

Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Achieve) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced financial results for the fourth quarter and full year 2025 and provided updates on the cytisinicline development program, including the announcement of its partnership with Adare Pharma Solutions (Adare). “Achieve is fully committed to bringing cytisinicline to the millions of people who continue to struggle with nicotine dependence and need a new solution to help...

PFNW permit renewal triples liquid processing capacity to 1.2 million gallons annually while backlog growth and international activity strengthen the Company’s growth platform ATLANTA, March 24, 2026 (GLOBE NEWSWIRE) — Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the fourth quarter and full year ended December 31, 2025. Mark Duff, President and Chief Executive Officer of the Company, commented, “During 2025, we focused on strengthening Perma-Fix’s operational foundation and positioning the Company for the next phase of growth tied to the U.S. Department of Energy’s (“DOE”) Hanford cleanup mission. While the timing of certain government programs affected activity levels during the year, we continued to progress in preparing our facilities,...

HANGZHOU, China, March 24, 2026 (GLOBE NEWSWIRE) — UTStarcom (the Company) (NASDAQ: UTSI), a global telecommunications infrastructure provider, today reported its unaudited financial results for the six months and full year ended December 31, 2025, and provided a business update. Business UpdateStrategic Pivot to AI Networking. UTStarcom recognizes AI Networking as a major market opportunity and is shifting its primary innovation and development efforts toward this sector, leveraging its deep heritage in cutting-edge optical networking technologies and intelligent network automation to address the infrastructure demands of the AI era. Amid the explosive growth of AI processing requirements, the need for highly efficient, low-latency backend networking has become a critical bottleneck. UTStarcom is addressing this challenge by...

Delivering on Strategy Commitments in Defining First Year Post-IPO Achieved Annual Operating Profit of $1.3 billion; Second Consecutive Year of Record Operating Profit Fourth Consecutive Year of Packaged Meats Segment Operating Profit Above $1 Billion Company Announces Dividend Increase to $1.25 per share in 2026SMITHFIELD, Va., March 24, 2026 (GLOBE NEWSWIRE) — Smithfield Foods, Inc. (Nasdaq: SFD), an American food company and an industry leader in value-added packaged meats and fresh pork, today reported results for its fiscal 2025 fourth quarter and year ended December 28, 2025. Full Year Fiscal 2025 Financial HighlightsNet sales of $15.5 billion, up 9.8% from fiscal year 2024 Operating profit of $1,292 million, up 15.6% from fiscal year 2024; Adjusted operating profit of $1,336 million, up 30.5% from fiscal year 2024 Operating...